ESTRO 2025 - Abstract Book

S2089

Clinical - Urology

ESTRO 2025

Results: Between July 2023 and July 2024, 12 patients were enrolled and treated. The median age was 66 years (range: 58 – 76), and the median follow-up duration was 4.1 months (range: 3 –9). No acute or late grade ≥2 gastrointestinal (GI) or genitourinary (GU) toxicities were observed. Grade 1 acute GU (dysuria) and GI (diarrhea) toxicities were reported in 16.6% and 8.3% of patients, respectively, and resolved within three months post-treatment. The median PSA nadir at six months post-treatment was 0.09 ng/mL (range: 0.04 – 0.25). At the last follow-up, no patient exhibited biochemical failure.

Conclusion: These findings suggest that post-prostatectomy SBRT is well-tolerated, with no significant increase in toxicity. However, longer follow-up and randomized trials comparing this approach with alternative radiotherapy regimens are necessary to confirm its efficacy and safety.

Keywords: SBRT, prostate bed, toxicity